PCSK9 inhibitor protects against myocardial ischemia-reperfusion injury via inhibiting LRP8/GPX4-mediated ferroptosis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.PCSK9 inhibitors protect heart tissue from damage caused by ischemia-reperfusion injury. This occurs by targeting LRP8 and inhibiting ferroptosis, a process involving iron and reactive oxygen species.
Area Of Science
- Cardiovascular Biology
- Cellular Pathology
- Biochemistry
Background
- Myocardial ischemia-reperfusion (I/R) injury exacerbates cardiac tissue damage through ferroptosis, a cell death pathway.
- Reactive oxygen species (ROS) and iron ions are key mediators in ferroptosis during I/R injury.
Purpose Of The Study
- To investigate the molecular mechanisms by which PCSK9 inhibition mitigates myocardial I/R injury.
- To explore the role of LRP8 and ferroptosis in the protective effects of PCSK9 inhibitors.
Main Methods
- Established myocardial I/R rat and H9c2 cell (OGD/R) models.
- Utilized STRING database and immunoprecipitation to verify PCSK9 inhibitor-LRP8 interaction.
- Assessed cell viability (CCK-8), infarct size (TTC), histological changes (H&E), and ferroptosis markers (DCFH-DA, ROS, iron, MDA, SOD).
Main Results
- PCSK9 inhibitor treatment significantly protected cardiomyocytes against OGD/R-induced damage.
- Inhibition of PCSK9 reduced myocardial infarction and pathological alterations in I/R rats.
- PCSK9 inhibitor modulated ferroptosis indicators and suppressed ferroptosis by targeting LRP8 and inhibiting GPX4/ROS.
Conclusions
- PCSK9 inhibitors attenuate myocardial I/R injury.
- The protective mechanism involves targeting LRP8 and modulating GPX4/ROS-mediated ferroptosis.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.